Latest revenue
$6.4M
as of 2026-03-31
Latest net income
$-90.1M
as of 2026-03-31
Net margin
-1408.6%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $313.5M
- Enterprise value
- $306.6M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 14.87×
- Dividend yield
- 0.0%
- 52-wk high
- $16.19
- 52-wk low
- $5.46
- Beta
- —
- Shares out
- 51.7M
Community sentiment
Where do you think RGNX is heading?
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Biological Products, (No Diagnostic Substances) (165 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
5-year trend
What this company does
ITEM 1. BUSINESS Overview We are a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Our investigational gene therapies are designed to deliver functional genes to address genetic defects in cells, enabling the production of therapeutic proteins or antibodies that are intended to impact disease. Through a single administration, gene therapy could potentially alter the course of disease significantly and deliver improved patient outcomes with long-lasting effects. Our investigational gene therapies use adeno-associated virus (AAV) vectors from our proprietary gene delivery platform, which we call our NAV® Technology…
AI summary unavailable — showing raw filing excerpt
Generated from RGNX's filing dated 2026-03-05
Key risks
ITEM 1A. RISK FACTORS You should carefully consider the risk factors set forth below as well as the other information contained in this Annual Report on Form 10-K and in our other public filings in evaluating our business. Any of the following risks could materially and adversely affect our business, financial condition or results of operations. In addition, these risks could cause actual results and developments to differ materially and adversely from those projected in the forward-looking statements contained in this Annual Report on Form 10-K (please read the Information Regarding Forward-Looking Statements appearing at the beginning of this Form 10-K). Additional risks and uncertainties…
AI summary unavailable — showing raw filing excerpt
Generated from RGNX's filing dated 2026-03-05
Profitability
Operating margin
-94.6%
66.2%Net margin
-113.8%
58.3%Return on equity
-74.7%
2.5%Return on assets
-42.8%
12.2%Leverage
Debt / equity
0.74×
50.5%Debt / assets
42.7%
29.0%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $6.4M | -92.8% | $-90.1M | -1580.4% | -1408.6% |
Q4 2025 2025-12-31 | $30.3M | +43.0% | $-73.2M | -43.1% | -241.4% |
Q3 2025 2025-09-30 | $29.7M | +22.9% | $-61.9M | -3.9% | -208.3% |
Q2 2025 2025-06-30 | $21.4M | -4.2% | $-64.8M | -22.3% | -303.3% |
Q1 2025 2025-03-31 | $89.0M | +469.8% | $6.1M | +109.6% | 6.8% |
Q4 2024 2024-12-31 | $21.2M | — | $-51.2M | — | -241.3% |
Q3 2024 2024-09-30 | $24.2M | -16.3% | $-59.6M | +3.7% | -246.3% |
Q2 2024 2024-06-30 | $22.3M | +11.6% | $-53.0M | +26.5% | -237.7% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Biological Products, (No Diagnostic Substances) · SIC 2836
Your notes
Keep private notes on RGNX — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$638.3K
Net activity
−$638.3K
Distinct insiders
2
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns RGNX
Institutional value
$148.1M
Total shares held
18.1M
Distinct holders
82
-89 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 5.8M | $48.5M | +26.0K (+0.5%) | Added |
| 2 | JPMORGAN CHASE & CO | 3.5M | $27.1M | -69.7K (-2.0%) | Trimmed |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 2.0M | $16.8M | — | New |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.0M | $8.5M | — | New |
| 5 | DIMENSIONAL FUND ADVISORS LP | 1.0M | $8.5M | +106.5K (+11.8%) | Added |
| 6 | Assenagon Asset Management S.A. | 980.6K | $8.2M | -179.8K (-15.5%) | Trimmed |
| 7 | Nuveen, LLC | 582.0K | $4.9M | -76.5K (-11.6%) | Trimmed |
| 8 | STIFEL FINANCIAL CORP | 392.8K | $3.3M | +57.7K (+17.2%) | Added |
| 9 | VANGUARD FIDUCIARY TRUST CO | 312.1K | $2.6M | — | New |
| 10 | Y-Intercept (Hong Kong) Ltd | 275.0K | $2.3M | — | New |
| 11 | UBS Group AG | 257.5K | $2.2M | +50.8K (+24.6%) | Added |
| 12 | DEUTSCHE BANK AG\ | 197.0K | $1.7M | +4.4K (+2.3%) | Added |
| 13 | Hudson Bay Capital Management LP | 180.0K | $1.5M | +40.0K (+28.6%) | Added |
| 14 | Invesco Ltd. | 158.8K | $1.3M | +926 (+0.6%) | Added |
| 15 | Bank of New York Mellon Corp | 140.2K | $1.2M | -5.4K (-3.7%) | Trimmed |
| 16 | Russell Investments Group, Ltd. | 113.4K | $950.5K | +103.7K (+1070.9%) | Added |
| 17 | JANE STREET GROUP, LLC | 105.5K | $884.5K | -91.0K (-46.3%) | Trimmed |
| 18 | Jefferies Financial Group Inc. | 95.4K | $799.5K | — | New |
| 19 | Connor, Clark & Lunn Investment Management Ltd. | 85.2K | $714.4K | — | New |
| 20 | RHUMBLINE ADVISERS | 60.5K | $506.9K | -5.3K (-8.1%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once RGNX's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.